Bio-Techne Corporation (TECH)

Bio-Techne's stock price has experienced fluctuations in the past six months, with a decline of 31.85% from July 15, 2024, to July 14, 2025. Key events impacting the stock include the Q3 2025 earnings report, which showed robust earnings driven by strong demand, and an equity buyback announcement of $500 million. Analyst ratings have varied, with some initiating coverage with a 'Buy' or 'Overweight' recommendation, while others have downgraded their outlook. Despite the recent stock decline, analysts maintain a moderately optimistic outlook, with a 'Moderate Buy' consensus rating.

Bio-Techne's products and services exhibit some demand seasonality, with the second half of the fiscal year tending to be stronger from a revenue perspective. This is attributed to customers spending more time at the bench without the interruptions of vacations that occur in the first half of the year.

Bio-Techne Corp. is a global life sciences company focused on developing, manufacturing, and selling reagents, instruments, and services for the research, diagnostic, and bioprocessing markets. The company operates in the Healthcare sector, specifically in Biotechnology & Medical Research and Medical - Biomedical and Genetics industries, and is segmented into Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment focuses on biological reagents, while the Diagnostics and Genomics segment develops and manufactures diagnostic products. Bio-Techne conducts research in areas such as cancer, cardiovascular, cell and gene therapy, and has expanded its portfolio through strategic acquisitions.

Bio-Techne is headquartered in Minneapolis, Minnesota, and has a global presence with over 3,000 employees across 34 locations worldwide, spanning five continents including North America, Europe, and Asia. The company has a sales subsidiary in Hong Kong and a new GMP factory in St. Paul, Minnesota. Bio-Techne leverages its global operational footprint to mitigate the impact of tariffs by diversifying instrument manufacturing locations.

Bio-Techne has maintained a strong brand reputation as a key player in the biotechnology sector, recognized for its innovative contributions. Media coverage has highlighted events related to the company, focusing on company updates and strategic partnerships. Notable events include partnerships with USP and Spear Bio, a focus on growth verticals, and leveraging AI capabilities.

Bio-Techne's ownership structure is primarily composed of institutional investors, who hold approximately 69.20% to 93.48% of the company's stock. Insiders own about 0.23%, and public companies and individual investors hold between 6.29% and 24.28%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Price T Rowe Associates Inc.